feburic能治好痛风吗？

Among the commonly used uric acid-lowering drugs, there is a new drug called febuxostat, which is a xanthine oxidase (XO) inhibitor. It binds to xanthine oxidase through a non-competitive mechanism, inhibits xanthine oxidase activity, inhibits the production of uric acid, and achieves the purpose of reducing acid.

feburic applied for listing in Japan in early 2004. In April 2008, the European Union first approved the marketing of feburic, with specifications of 80mg and 120mg, and the trade name "Adenuric". It is used to treat chronic hyperuricemia with uric acid deposition (including patients with gout stones and/or gouty arthritis, or patients with a history of this). The FDA approved the marketing of feburic in February 2009 for the long-term control of hyperuricemia in patients with gout. It was approved to be listed in China in 2013. So, can feburic cure gout?

According to Medical Companion Travel, feburic cannot cure gout, but can alleviate the patient's symptoms. It is recommended that patients follow the doctor's instructions as much as possible during drug treatment, and do not increase or decrease the dosage without permission.

The starting dose of feburic is 40 mg once daily. If the blood uric acid level is still not less than 6 mg/dl (approximately 360 μmol/L) after 2 weeks, it is recommended that the dose be increased to 80 mg once a day.

Food and antacid effects do not need to be considered when administering the drug. Patients with mild or moderate hepatic insufficiency (Child-Pugh Class A, B) do not need to adjust the dosage. Patients with severe hepatic insufficiency (Child-Pugh Class C) should use feburic with caution.

Special populations: Patients with hepatic impairment: No dose adjustment is required for patients with mild or moderate hepatic impairment (Child-Pugh A, B). The efficacy and safety of feburic (febuxostat) in patients with severe hepatic insufficiency (Child-Pugh class C) have not been studied, so feburic (febuxostat) should be used with caution in these patients.

Patients with renal insufficiency: Patients with mild or moderate renal insufficiency (Clcr30-89 ml/min) do not need to adjust the dosage. The recommended starting dose of feburic is 40 mg once daily. If the blood uric acid level is still not less than 6 mg/dl after 2 weeks, it is recommended that the dose be increased to 80 mg once a day. There are insufficient study data in patients with severe renal insufficiency (Clcr <30ml/min), so feburic (febuxostat) should be used with caution in these patients. Uric Acid Levels Two weeks after starting treatment with febuxostat, it is possible to assess whether the serum uric acid level has reached the target value (less than 6 mg/dl).